Effect of C9-methyl substitution and C8-C9 conformational restriction on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d] pyrimidines

被引:43
作者
Gangjee, A [1 ]
Zeng, YB
McGuire, JJ
Kisliuk, RL
机构
[1] Duquesne Univ, Grad Sch Pharmaceut Sci, Div Med Chem, Pittsburgh, PA 15282 USA
[2] Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA
[3] Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA
关键词
D O I
10.1021/jm000130i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-[4-[1-Methyl-2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid(5) and its C8-C9 conformationally restricted E- and Z-isomers (6 and 7) were designed and synthesized in order to investigate the effect of incorporating a methyl group at the C9 position and of conformational restriction at the C8-C9 bridge of N-[4-[2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid (1) with respect to dihydrofolate reductase (DHFR) inhibitory activity as well as antitumor activity. The compounds were synthesized by a Wittig reaction of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine with ethyl 4-acetylbenzoate followed by catalytic reduction, hydrolysis, and standard peptide coupling with diethyl L-glutamate. The biological results indicated that the addition of a 9-methyl group to the C8-C9 bridge, as in 5, increased recombinant human (rh) DHFR inhibitory potency (IC50 = 0.42 CIM) as well as the potency against the growth inhibition of tumor cells in culture (CCRF-CEM EC50 = 29 nM, A253 EC50 = 28.5 nM, and FaDu EC50 = 17.5 nM) compared with the g-desmethyl analogue 1. However, the conformationally restricted 4:1 Z/E mixture of 7 and 6 was less potent than 5 in both assays, and the pure E-isomer 6 was essentially inactive. These three classical analogues were also evaluated as inhibitors of Lactobacillus casei, Escherichia coli, and rat and rh thymidylate synthase (TS) and were found to be weak inhibitors. All three analogues 5-7 were good substrates for human folylpolyglutamate synthetase (FPGS). These data suggested that; FPGS is relatively tolerant to different conformations in the bridge region. Further evaluation of the cytotoxicity of 5 and 7 in methotrexate (MTX)-resistant CCRF-CEM cell sublines suggested that polyglutamylation was crucial. for their mechanism of action. Metabolite protection studies of 5 implicated DHFR as the primary intracelluar target. Compound 5 showed GI(50) values in 10(-9)-10(-7) M range against more than 30 tumor cell lines in culture.
引用
收藏
页码:3125 / 3133
页数:9
相关论文
共 31 条
[1]   THE RENEWED POTENTIAL FOR FOLATE ANTAGONISTS IN CONTEMPORARY CANCER-CHEMOTHERAPY [J].
BERMAN, EM ;
WERBEL, LM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :479-485
[2]  
BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P92
[3]   THE CATALYTIC MECHANISM AND STRUCTURE OF THYMIDYLATE SYNTHASE [J].
CARRERAS, CW ;
SANTI, DV .
ANNUAL REVIEW OF BIOCHEMISTRY, 1995, 64 :721-762
[4]  
CODY V, 1992, ANTI-CANCER DRUG DES, V7, P483
[5]  
DAVISSON VJ, 1989, J BIOL CHEM, V264, P9145
[6]  
DEGRAW JI, 1986, J HETEROCYCLIC CHEM, V23, P1, DOI 10.1002/jhet.5570230101
[7]   SYNTHESIS AND BIOLOGICAL-ACTIVITY OF RESOLVED C-10 DIASTEREOMERS OF 10-METHYL-10-DEAZAMINOPTERIN AND 10-ETHYL-10-DEAZAMINOPTERIN [J].
DEGRAW, JI ;
CHRISTIE, PH ;
TAGAWA, H ;
KISLIUK, RL ;
GAUMONT, Y ;
SCHMID, FA ;
SIROTNAK, FM .
JOURNAL OF MEDICINAL CHEMISTRY, 1986, 29 (06) :1056-1061
[8]   SYNTHESIS AND ANTIFOLATE PROPERTIES OF 10-ALKYL-8,10-DIDEAZAMINOPTERINS [J].
DEGRAW, JI ;
CHRISTIE, PH ;
BROWN, EG ;
KELLY, LF ;
KISLIUK, RL ;
GAUMONT, Y ;
SIROTNAK, FM .
JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (03) :376-380
[9]  
FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[10]  
2-J